IMMUNODEFICIENCY 46
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency.
|
26642240 |
2016 |
IMMUNODEFICIENCY 46
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency.
|
26642240 |
2016 |
IMMUNODEFICIENCY 46
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
IMMUNODEFICIENCY 46
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Internalization experiments using a breast cancer cell line that overexpresses the transferrin receptor on its surface showed that the holo-transferrin-polymer conjugate was successfully internalized by cells in a mechanism consistent with receptor-mediated endocytosis.
|
30920802 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer.
|
31649854 |
2019 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TFRC expression was detected in various breast cancer tissues using immunohistochemistry and in various breast cancer cells using western blotting.
|
31173262 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent research demonstrated that unmodified human heavy chain ferritin binds to its receptor, transferrin receptor 1 (TfR1), in different types of tumor tissues, including lung and breast cancer, thus highlighting the potential use of ferritin for tumor-targeting applications.
|
31494184 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this work, we have used Nd-labeled antibodies to tag the TfR1 present on the cell surface of two cell models of breast cancer with different malignancy (MCF7 and MDA-MB 231).
|
31694367 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
|
31495855 |
2019 |
Iron deficiency anemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combination of hemoglobin and transferrin receptor defined IDA/NIDA.
|
30575959 |
2019 |
Iron deficiency anemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic power for soluble transferrin receptor/log ferritin index (0.864) was superior to soluble transferrin receptor (0.768) in iron deficiency anemia recognition.
|
30538074 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
|
31495855 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TFRC expression was detected in various breast cancer tissues using immunohistochemistry and in various breast cancer cells using western blotting.
|
31173262 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Internalization experiments using a breast cancer cell line that overexpresses the transferrin receptor on its surface showed that the holo-transferrin-polymer conjugate was successfully internalized by cells in a mechanism consistent with receptor-mediated endocytosis.
|
30920802 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this work, we have used Nd-labeled antibodies to tag the TfR1 present on the cell surface of two cell models of breast cancer with different malignancy (MCF7 and MDA-MB 231).
|
31694367 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer.
|
31649854 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent research demonstrated that unmodified human heavy chain ferritin binds to its receptor, transferrin receptor 1 (TfR1), in different types of tumor tissues, including lung and breast cancer, thus highlighting the potential use of ferritin for tumor-targeting applications.
|
31494184 |
2019 |
Iron deficiency anemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Soluble transferrin receptor (sTfR), a truncated extracellular form of TfR in serum, is an important marker of iron deficiency anemia (IDA) and bone marrow failure in cancer patients.
|
29271190 |
2018 |
Iron deficiency anemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Malaria exacerbates inflammation-associated elevation in ferritin and soluble transferrin receptor with only modest effects on iron deficiency and iron deficiency anaemia among rural Zambian children.
|
29121448 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer.
|
28223798 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
To develop 6-O-palmitoyl-ascorbic acid-based niosomes targeted to transferrin receptor for intravenous administration of tocotrienols (T3) in breast cancer.
|
28972460 |
2017 |
Iron deficiency anemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reticulocyte hemoglobin content has a high sensitivity and specificity in the diagnosis of iron deficiency anemia, and its comprehensive diagnostic efficacy is better than other traditional indicators-such as serum ferritin and serum transferrin receptor.
|
28468320 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer.
|
28223798 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To develop 6-O-palmitoyl-ascorbic acid-based niosomes targeted to transferrin receptor for intravenous administration of tocotrienols (T3) in breast cancer.
|
28972460 |
2017 |